Antisense strategies to inhibit restenosis

M Lee1, A D Simon, C A Stein

  • 1Columbia University College of Physicians & Surgeons, Department of Medicine, New York, NY 10032, USA.

Insights

Phosphorothioate oligodeoxynucleotides show promise in inhibiting vascular smooth muscle cell proliferation and migration, key factors in restenosis after coronary procedures. These compounds offer novel therapeutic strategies for preventing arterial narrowing and promoting vascular healing.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biotechnology

Background:

  • Restenosis following percutaneous transluminal coronary angioplasty (PTCA) and stenting is a significant clinical challenge.
  • Vascular smooth muscle cell (SMC) proliferation and migration are critical in restenosis pathogenesis.
  • Phosphorothioate (PS) oligodeoxynucleotides have emerged as potential therapeutic agents.

Purpose of the Study:

  • To investigate the efficacy of PS oligodeoxynucleotides in inhibiting SMC proliferation and migration.
  • To explore the mechanisms underlying the inhibitory effects of PS oligodeoxynucleotides.
  • To evaluate novel strategies for restenosis inhibition.

Main Methods:

  • PS oligodeoxynucleotides targeting genes like c-myb, c-myc, cdc2 kinase, cdk2 kinase, and PCNA were used.
  • In vitro studies assessed SMC proliferation, migration, and adhesion.
  • In vivo studies utilized rat carotid and porcine coronary artery models of balloon injury.
  • Experiments included cytidine homopolymers (S-dC28) and guanosine-rich oligodeoxynucleotides (ZK10).
  • Novel strategies like E2F transcription decoys and antisense oligonucleotides against bcl-xL were explored.

Main Results:

  • PS oligodeoxynucleotides targeting specific genes inhibited in vitro SMC proliferation and migration.
  • Adventitial or intraluminal delivery of these PS oligodeoxynucleotides inhibited in vivo neointimal formation.
  • Non-G-quartet, non-sequence-specific PS oligodeoxynucleotides (S-dC28) inhibited SMC functions by binding to PDGF and bFGF.
  • ZK10 showed potent in vitro inhibition, with comparable in vivo effects to S-dC28.
  • PS oligodeoxynucleotides exhibited non-sequence-specific immunomodulatory effects.
  • E2F decoys and bcl-xL antisense oligonucleotides reduced neointimal lesion formation and promoted SMC apoptosis.

Conclusions:

  • PS oligodeoxynucleotides effectively inhibit SMC proliferation, migration, and neointimal formation.
  • Both sequence-dependent and non-sequence-specific mechanisms contribute to their inhibitory effects.
  • Novel strategies targeting cell cycle regulation and apoptosis offer promising avenues for restenosis treatment.
  • Further research into PS oligodeoxynucleotide properties and delivery methods is warranted.

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...